4.5 Article

Construction of a FRAXA® model for the assessment of fracture probability in Canada and implications for treatment

Journal

OSTEOPOROSIS INTERNATIONAL
Volume 22, Issue 3, Pages 817-827

Publisher

SPRINGER LONDON LTD
DOI: 10.1007/s00198-010-1464-2

Keywords

Bone mineral density; Canada; Clinical risk factors; Fracture; FRAX (R); Osteoporosis

Funding

  1. International Osteoporosis Foundation
  2. European Society
  3. Merck Frosst Canada Ltd
  4. Sanofi-Aventis
  5. Procter & Gamble Pharmaceuticals Canada, Inc.
  6. Novartis
  7. Amgen Pharmaceuticals Canada, Inc.
  8. Innovus 3M
  9. Genzyme Canada
  10. Amgen
  11. Eli Lilly
  12. Merck
  13. Proctor Gamble
  14. Warner-Chilcott
  15. Servier
  16. Wyeth-Ayerst
  17. Nycomed
  18. AstraZeneca
  19. Pfizer
  20. Bayer
  21. Procter Gamble
  22. Lilly
  23. Roche
  24. Hologic
  25. Astra Zeneca
  26. GSK
  27. Sanofi Aventis
  28. Wyeth
  29. Bristol-Myers Squibb

Ask authors/readers for more resources

We describe the creation of a FRAXA (R) model for the assessment of fracture probability in Canadian men and women, calibrated from national hip fracture and mortality data. This FRAX tool was used to examine possible thresholds for therapeutic intervention in Canada in two large complementary cohorts of women and men. To evaluate a Canadian World Health Organization (WHO) fracture risk assessment (FRAXA (R)) tool for computing 10-year probabilities of osteoporotic fracture. Fracture probabilities were computed from national hip fracture data (2005) and death hazards (2004) for Canada. Probabilities took account of age, sex, clinical risk factors (CRFs), and femoral neck bone mineral density (BMD). Treatment implications were studied in two large cohorts of individuals age 50 years and older: the population-based Canadian Multicentre Osteoporosis Study (4,778 women and 1,919 men) and the clinically referred Manitoba BMD Cohort (36,730 women and 2,873 men). Fracture probabilities increased with age, decreasing femoral neck T-score, and number of CRFs. Among women, 10.1-11.3% would be designated high risk based upon 10-year major osteoporotic fracture probability exceeding 20%. A much larger proportion would be designated high risk based upon 10-year hip fracture probability exceeding 3% (25.7-28.0%) or osteoporotic BMD (27.1-30.9%), and relatively few from prior hip or clinical spine fracture (1.6-4.2%). One or more criteria for intervention were met by 29.2-34.0% of women excluding hip fracture probability (35.3-41.0% including hip fracture probability). Lower intervention rates were seen among CaMos (Canadian Multicentre Osteoporosis Study) men (6.8-12.9%), but in clinically referred men from the Manitoba BMD Cohort, one or more criteria for high risk were seen for 26.4% excluding hip fracture probability (42.4% including hip fracture probability). The FRAX tool can be used to identify intervention thresholds in Canada. The FRAX model supports a shift from a dual X-ray absorptiometry (DXA)-based intervention strategy, towards a strategy based on fracture probability for a major osteoporotic fracture.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available